Pulmonary arterial hypertension targeted for new treatment by ºÚÁϳԹÏÍø of Sheffield scientists
Scientists at the ºÚÁϳԹÏÍø of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).